New treatment for drug-resistant gonorrhea, Zoliflodacin, to enter global Phase 3 clinical trial

On Friday, the World Health Organization (WHO) released alarming new data showing that of 77 countries surveyed across the world, more than 60% report resistance to the last-resort treatment for gonorrhea. On the same day, Entasis Therapeutics announced that Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing ["]

The post New treatment for drug-resistant gonorrhea, Zoliflodacin, to enter global Phase 3 clinical trial appeared first on Outbreak News Today.